The UK's medicines industry is one of the country's leading manufacturing sectors, with exports worth around £30bn.
The Partnership aims to ensure that the UK continues to be an attractive place for this high-value industry to secure exports, provide high skilled job opportunities and contribute to solving the country's productivity puzzle.
The UK Life Sciences Industrial Strategy recognised the sector’s high productivity and the MMIP is now an expert group under the direction of the Life Sciences Council.
Working closely with key government organisations including the Medicines and Healthcare products Regulatory Authority (MHRA), UK Trade and Investment (UKTI), Innovate UK and the Office for Life Sciences (OLS), MMIP is continuously working to sustain the UK's leading position in medicines manufacturing technologies, including those related to advanced therapy medicinal products (ATMPs), continuous production and digitalisation.
During the second half of 2020, the Technology & Innovation workstream developed a roadmap, building on the MMIP mission, charting progress to date and describing how the continuing work of the MMIP will be organised under five ‘grand challenges’.
MMIP is divided into six workstreams. All of these workstreams are supported by overarching communications work and building the manufacturing community to ensure it speaks with one voice.
These workstreams are:
MMIP also works to build the medicines manufacturing community.
MMIP is supported by the ABPI, the BioIndustry Association (BIA) and the Knowledge Transfer Network, and includes leadership from Allergan Biologics, AstraZeneca, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Pfizer and ReNeuron. It has a senior project director, employed by the ABPI, and additional dedicated resources provided by partners.
For more information please contact the MMIP Operations Team:
The regulatory environment workstream is trying to maximise innovative processes by highlighting existing regulatory flexibility and the positive UK regulatory landscape to industry.
As part of its programme of work, the Medicines Manufacturing Industry Partnership (MMIP) seeks to ensure that the UK has an adaptive workforce with relevant skills to sustain the future requirements of the UK medicines manufacturing industry.
The supply chain workstream seeks to deliver capable and connected infrastructure, building understanding of medicines manufacturing supply chains, identifying opportunities to maximise supply and fostering non-competitive sector collaboration.
The technology workstream seeks to understand and pursue the future needs of the medicines manufacturing industry.
The Knowledge Transfer Network (KTN) have created a tool which aims to provide a visual dynamic representation of the UK Medicines Manufacturing Innovation Landscape.